Novartis Q3 Core Beats, FY Core Operating Income Guidance Raised Despite $1.9B Impairment
NVS sits 29% above its 52-week low of $121.57.
Summary
Novartis grew Q3 core operating income 11% to $6.0B and raised full-year core operating income guidance, while a $1.9B del-desiran impairment and $0.6B onerous contract provision dragged reported net income down 70%.
Updates
· Seeking Alpha — Novartis shares rose 1.6% to $156.26 in early trading after the guidance upgrade.
- Core Results — Core operating income rose 10% cc to $6B, exceeding analyst expectations, and core EPS climbed 8% cc to $2.46.
- Reported Results — Reported operating income fell 61% cc to $1.84B and net income dropped 71% to $1.2B.
- Product Sales — Kisqali sales rose 37% cc, Kesimpta 22%, Scemblix 67% and Leqvio 63%.
All 4 details
- Core EPS climbed 8% cc to $2.46.
- Kisqali sales rose 37% cc, Kesimpta 22%, Scemblix 67%, Leqvio 63%.
- Core operating income rose 10% cc to $6B, exceeding analyst expectations.
- Reported operating income fell 61% cc to $1.84B; net income dropped 71% to $1.2B.
Key Events · Earnings and Guidance · NVS
-
Q3 Core Operating Income Up 11%
Core operating income reached USD 6.036B on net sales of USD 14.522B (+4%, +4% cc), lifting the core operating margin to 41.6% from 39.3% a year earlier.
-
Full-Year Core Guidance Raised
FY 2026 core operating income is now expected to be 'in line to grow low single-digit', upgraded from a prior expectation of declining low single-digit; net sales guidance stays at low single-digit growth.
-
$1.9B Del-Desiran Impairment Hits Reported Earnings
A USD 1.94B partial impairment of the del-desiran IPR&D asset cut its carrying value to USD 5.54B, driving operating income down 59% to USD 1.843B and net income down 70% to USD 1.196B; a USD 0.6B onerous supply-contract provision added to other expense.
-
Net Debt Nearly Doubles to $37.4B
Net debt rose from USD 21.9B at December 31, 2025 to USD 37.4B at September 30, 2026, after USD 12.8B of business acquisitions, a USD 9.1B dividend and USD 4.8B of treasury share purchases, partly offset by USD 14.0B of free cash flow.
Analysis · NVS · Life Sciences
Core operating income rose 11% to $6.0B on a 41.6% margin, and management lifted full-year core operating income guidance to 'in line to grow low single-digit' from a prior expected decline. The operating business is performing better than the company told investors three months ago. Headline numbers look ugly only because of two non-cash items tied to the failed del-desiran DM1 program: a $1.9B partial impairment of the Avidity-acquired IPR&D asset and a $0.6B onerous supply-contract provision. Those drove reported operating income down 59% and net income down 70%, but they do not touch cash generation, which stayed strong at $5.1B for the quarter. The offsetting cost is balance sheet capacity: net debt nearly doubled to $37.4B after $12.8B of acquisitions and a $9.1B dividend, so future bolt-ons are less free than they were at the start of the year.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 36.5% of the 953 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.66%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NVS was trading at $156.26 on NYSE in the Life Sciences sector, with a market capitalization of approximately $281.9B. The 52-week trading range was $121.57 to $170.46. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.